Drug Information

Drug General Information
Drug ID
D0Q0EF
Former ID
DNCL003122
Drug Name
ITI-007
Indication Schizophrenia; Sleep maintenance insomnia [ICD9: 295, 307.41, 307.42, 327.0, 780.51, 780.52; ICD10:F20, F51.0, G47.0] Phase 3 [525226], [549912]
Company
Intra-Cellular Therapies
Target and Pathway
Target(s) Sodium-dependent serotonin transporter Target Info Antagonist [551041]
5-hydroxytryptamine 2A receptor Target Info Antagonist [551041]
KEGG Pathway Serotonergic synapsehsa04020:Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channels
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway 5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling events
WikiPathways Monoamine Transport
SIDS Susceptibility Pathways
NRF2 pathway
Synaptic Vesicle Pathway
Serotonin Transporter ActivityWP733:Serotonin Receptor 2 and STAT3 Signaling
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 525226ClinicalTrials.gov (NCT02469155) A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment.
Ref 549912Clinical pipeline report, company report or official report of Intra-Cellular Therapies.
Ref 551041Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.